Updating the WHO target product profile for next-generation Mycobacterium tuberculosis drug susceptibility testing at peripheral centres.

Autor:	MacLean EL; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada.; McGill International TB Centre, Montreal, Canada., Miotto P; Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy., González Angulo L; Global TB Programme, World Health Organization, Geneva, Switzerland., Chiacchiaretta M; Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy., Walker TM; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam., Casenghi M; Department of Innovation and New Technology, Elizabeth Glaser Paediatric AIDS Foundation, Geneva, Switzerland., Rodrigues C; P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India., Rodwell TC; FIND, Geneva, Switzerland.; Department of Medicine, University of California, San Diego, La Jolla, California, United States of America., Supply P; Univ. de Lille, CNRS, INSERM, CHU Lille; Institut Pasteur de Lille, U1019-UMR 9017-CIIL (Center for Infection and Immunity of Lille), Lille, France., André E; Laboratory of Clinical Bacteriology and Mycology, Dept of Microbiology and Immunology, KU Leuven, Leuven, Belgium.; Department of Laboratory Medicine, UZ Leuven Hospitals, Leuven, Belgium., Kohli M; FIND, Geneva, Switzerland., Ruhwald M; FIND, Geneva, Switzerland., Cirillo DM; Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy., Ismail N; Global TB Programme, World Health Organization, Geneva, Switzerland., Zignol M; Global TB Programme, World Health Organization, Geneva, Switzerland.
Jazyk:	angličtina
Zdroj:	PLOS global public health [PLOS Glob Public Health] 2023 Mar 31; Vol. 3 (3), pp. e0001754. Date of Electronic Publication: 2023 Mar 31 (Print Publication: 2023).
DOI:	10.1371/journal.pgph.0001754
Abstrakt:	There were approximately 10 million tuberculosis (TB) cases in 2020, of which 500,000 were drug-resistant. Only one third of drug-resistant TB cases were diagnosed and enrolled on appropriate treatment, an issue partly driven by a lack of rapid, accurate drug-susceptibility testing (DST) tools deployable in peripheral settings. In 2014, World Health Organization (WHO) published target product profiles (TPPs) which detailed minimal and optimal criteria to address high-priority TB diagnostic needs, including DST. Since then, the TB community's needs have evolved; new treatment regimens, changes in TB definitions, further emergence of drug resistance, technological advances, and changing end-users requirements have necessitated an update. The DST TPP's revision was therefore undertaken by WHO with the Stop TB Partnership New Diagnostics Working Group. We describe the process of updating the TPP for next-generation TB DST for use at peripheral centres, highlight key updates, and discuss guidance regarding technical and operational specifications. Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: PS is a consultant for Genoscreen. (Copyright: © 2023 MacLean et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu